Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | PSMD10 | O75832 | 1/20 | 0.35 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.35 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP8 | P22894 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16726897 | 1.00 | STAT3 (0.39) | STAT3ALDH1A1NR1D1KMT2ACA12 | |
| SCHEMBL29467660 | 1.00 | STAT3 (0.39) | STAT3ALDH1A1NR1D1KMT2ACA12 | |
| SCHEMBL40180 | 1.00 | STAT3 (0.39) | STAT3ALDH1A1NR1D1KMT2ACA12 | |
| SCHEMBL15675910 | 1.00 | STAT3 (0.39) | STAT3ALDH1A1NR1D1KMT2ACA12 | |
| SCHEMBL18383704 | 1.00 | STAT3 (0.39) | STAT3ALDH1A1NR1D1KMT2ACA12 | |
| SCHEMBL25403855 | 1.00 | STAT3 (0.39) | STAT3ALDH1A1NR1D1KMT2ACA12 | |
| SCHEMBL16329525 | 1.00 | STAT3 (0.39) | STAT3ALDH1A1NR1D1KMT2ACA12 | |
| SCHEMBL19299762 | 1.00 | STAT3 (0.39) | STAT3ALDH1A1NR1D1KMT2ACA12 | |
| SCHEMBL20529483 | 1.00 | STAT3 (0.39) | STAT3ALDH1A1NR1D1KMT2ACA12 | |
| SCHEMBL27443065 | 1.00 | STAT3 (0.39) | STAT3ALDH1A1NR1D1KMT2ACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024108009-A1 | DYRK/CLK PROTACS AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024108009-A1 | DYRK/CLK PROTACS AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20240050576-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2024-02-15 | — | — | US | disclosed |
| US-20230149550-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
| EP-3724180-B1 | COMPOUNDS FOR THE DEGRADATION OF STK4 AND TREATMENT OF HEMATOLOGIC MALIGNANCIES | DANA FARBER CANCER INST INC (US) | 2023-02-22 | — | — | EP | disclosed |
| EP-4100404-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| US-11447467-B2 | Compounds for the degradation of STK4 and treatment of hematologic malignancies | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| WO-2021158707-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. (US) | 2021-08-12 | — | — | WO | disclosed |
| US-20200331889-A1 | COMPOUNDS FOR THE DEGRADATION OF STK4 AND TREATMENT OF HEMATOLOGIC MALIGNANCIES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-22 | — | — | US | disclosed |
| US-RE44022-E1 | Cyclic peptides, method for preparing and use as angiogenesis inhibitors or activators | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2013-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149550-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | DMPK, DTYMK, MYCBP | STAT3 2224/4885ALDH1A1 4368/4885NR1D1 3435/4885 |
| US-11447467-B2 | Compounds for the degradation of STK4 and treatment of hematologic malignancies | STK4, STK11, STK16 | STAT3 449/4885ALDH1A1 1320/4885NR1D1 1259/4885 |
| US-20200331889-A1 | COMPOUNDS FOR THE DEGRADATION OF STK4 AND TREATMENT OF HEMATOLOGIC MALIGNANCIES | STK4, STK11, STK16 | STAT3 449/4885ALDH1A1 1320/4885NR1D1 1259/4885 |
| US-20240050576-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ZFX, GRN, F13B | STAT3 1074/4885ALDH1A1 4800/4885NR1D1 2337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.